For anyone wishing to read a very comprehensive analysis of Prima Biomed, the Southern Cross Equities did produce a very positive and informative analyst report back in May 2010 (Share price was $0.14). It gave PRR a 12 months target base price of $0.60 with the opportunistic case of $1.12. All these figures were based on CVac alone and assumed no value to HPV Vaccine and Cripto-1 Antibody or the 7% interest in Trillium Therapeutics. It also assume that trials were fully funded using convertible notes to Springtree i.e. fully diluted of 1.081b shares. Note: Based on the latest appendix 3B we currently have 768.5m listed shares and 105.3m listed options.
In the report it lists out a number of reasons to invest in PRR. I will just highlight a few point from the report.
i. Performed well in IIa results
ii. CVac able to be applied to other forms of cancer, beside Ovarian.
iii. Ovarian cancer worth $2-3b annually and will possibly replace chemotherapy and become standard of care.
iv. Emphasized the strong management in place.
However, what I like about the report was the layman's term used in describing the CVac Phase IIa trial results. 4 of the 21 late staged ovarian patient registered a positive response. This 19% response rate is phenomenon as all the patient have previously failed other therapies such that based on the SCE report anything above 10% is remarkable. In addition nearly half the patient gained some form of benefit and the response was long ranging from 27-44 weeks. And let's no forget the most important issue is safety. No safety issue was measured. Showing its is superiority to chemo and radio.
I highly recommend people to read the report to gain a better understanding of what the company is trying to accomplish in the near future.
- Forums
- ASX - By Stock
- IMM
- knowing risk and why it is mitigated
knowing risk and why it is mitigated, page-7
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
31.0¢ |
Change
-0.005(1.59%) |
Mkt cap ! $450.9M |
Open | High | Low | Value | Volume |
30.5¢ | 32.0¢ | 30.5¢ | $922.9K | 2.963M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 149460 | 30.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.0¢ | 30000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 149460 | 0.305 |
3 | 105779 | 0.300 |
5 | 77490 | 0.295 |
5 | 108515 | 0.290 |
4 | 86956 | 0.285 |
Price($) | Vol. | No. |
---|---|---|
0.310 | 30000 | 1 |
0.315 | 30416 | 1 |
0.320 | 265031 | 7 |
0.325 | 250558 | 5 |
0.330 | 37846 | 2 |
Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |